Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir (Articolo in rivista)

Type
Label
  • Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir (Articolo in rivista) (literal)
Anno
  • 2006-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1089/aid.2006.22.132 (literal)
Alternative label
  • Bongiovanni, M; Bini, T; Cicconi, P; Landonio, S; Meraviglia, P; Testa, L; Di Biagio, A; Chiesa, E; Tordato, F; Biasi, P; Adorni, F; Monforte, AD (2006)
    Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir
    in AIDS research and human retroviruses
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Bongiovanni, M; Bini, T; Cicconi, P; Landonio, S; Meraviglia, P; Testa, L; Di Biagio, A; Chiesa, E; Tordato, F; Biasi, P; Adorni, F; Monforte, AD (literal)
Pagina inizio
  • 132 (literal)
Pagina fine
  • 138 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 22 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 7 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 2 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • University of Milan; L Sacco; L Sacco; Busto Arsizio Hosp; University of Genoa; Consiglio Nazionale delle Ricerche (CNR) (literal)
Titolo
  • Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir (literal)
Abstract
  • We studied 382 multiexperienced HIV-infected patients followed up for >= 3 months after starting lopinavir/ri-tonavir (LPV/r) to identify the factors predicting hypertriglyceridemia and high non-HDL cholesterol levels (triglycerides >= 200 mg/dl and/or non-HDL cholesterol >= 190 mg/dl) after 6 and 12 months of LPV/r exposure. The predictors of hypertriglyceridemia were higher baseline triglyceride levels [OR: 2.28 (95% CI: 1.67-3.12) for each additional 100 mg/dl; p = 0.001], the total duration of antiretroviral treatment [OR: 1.26 (95% CI: 1.12-1.41) for each additional year; p = 0.01], CDC stage C (OR: 2.06; 95% CI: 1.24-3.88; p = 0.02), and male gender (OR: 2.52; 95% CI: 1.42-4.74; p = 0.02); intravenous drug abusers seem less likely to develop the event (OR: 0.52; 95% CI: 0.37-0.92; p = 0.03). The predictors of high non- HDL cholesterol levels were higher baseline levels [OR: 3.92 (95% CI: 1.92-6.24) for each additional 100 mg/dl; p = 0.001) and the combination of NRTIs and NNRTIs with LPV/r (OR: 1.83; 95% CI: 1.10-3.69; p = 0.03). The 75 patients stopping LPV/r showed a significant reduction in median triglyceride and non-HDL cholesterol levels after 3 months of 39 mg/dl and 20 mg/dl (p = 0.01 for both), respectively. Patients with high triglyceride and non-HDL cholesterol levels at the start of LPV/r treatment are at higher risk of developing hyperlipidemia. (literal)
Autore CNR

Incoming links:


Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it